Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qorvo (QRVO) and Skyworks (SWKS) double upgraded to Buy from Underperform at BofA/Merrill. 2. Fate Therapeutics (FATE) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jim Birchenough citing this weekend's update for the company's iPSC-derived NK-cell therapeutics pipeline, initial data for iPSC NKcell therapies FT500 and FT516, and updated comments on CD19 CAR-NK therapeutic FT596. 3. Wingstop (WING) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Katherine Fogertey saying while the shares are up over 30% over the past year, they have lagged the S&P 500 by over 30% since August 22 and now trade at a discount to peers. 4. Huntsman (HUN) and Fortive (FTV) upgraded to Buy from Neutral at Citi. 5. Dow Inc. (DOW) and Kraton (KRA) upgraded to Buy from Hold at SunTrust. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

JPMorgan analyst Jeffrey Zekauskas upgraded Dow Inc. to Overweight from Neutral with a price target of $61, up from $55. The analyst says Dow is capable of outperforming because it is a beneficiary of higher oil prices, it has a "durable" 5% dividend yield, its value is sensitive to acceleration in global economic activity, and its downside risk is "cushioned by the existence of global political tensions." Dow benefits from a higher oil price because its raw materials slate is largely low-cost natural gas liquids, the analyst tells investors in a research note.

JPMorgan upgraded Dow Inc. to Overweight from Neutral with a $61 price target.

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.  1... To see the rest of the story go to thefly.com. See Story Here

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here

Sees Q2 revenue $1.6B, consensus $1.62B. The company said, "For the second quarter of 2024, Fortive anticipates revenue of approximately $1.6 billion, diluted net earnings per share of $0.57 to $0.60 and adjusted diluted net earnings per share of $0.90 to $0.93."